Health
BreezeBio Raises $60 Million to Develop mRNA-Based Diabetes Therapy
Polymer nanoparticle startup BreezeBio has raised $60 million to advance an mRNA-based therapy for diabetes that uses novel delivery technology to target pancreatic cells. The approach could offer a fundamentally different treatment paradigm for the hundreds of millions living with the disease.
Key Takeaways
- BreezeBio raised $60M to develop mRNA therapy delivered via polymer nanoparticles to pancreatic cells
- Polymer nanoparticles overcome lipid nanoparticle limitations by targeting organs beyond the liver
- Could shift diabetes treatment from daily management to addressing root biology of the disease
- Clinical trials could begin within two to three years if preclinical data holds
DE
DT Editorial AI··via endpoints.news